KR20190138650A - 반흔성 안구 염증성 장애의 치료를 위한 코버신 - Google Patents

반흔성 안구 염증성 장애의 치료를 위한 코버신 Download PDF

Info

Publication number
KR20190138650A
KR20190138650A KR1020197031685A KR20197031685A KR20190138650A KR 20190138650 A KR20190138650 A KR 20190138650A KR 1020197031685 A KR1020197031685 A KR 1020197031685A KR 20197031685 A KR20197031685 A KR 20197031685A KR 20190138650 A KR20190138650 A KR 20190138650A
Authority
KR
South Korea
Prior art keywords
seq
ala
coversin
asp
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031685A
Other languages
English (en)
Korean (ko)
Inventor
윈 에이치 웨스턴-데이비스
Original Assignee
볼루션 이뮤노 파마슈티컬스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706398.3A external-priority patent/GB201706398D0/en
Application filed by 볼루션 이뮤노 파마슈티컬스 에스에이 filed Critical 볼루션 이뮤노 파마슈티컬스 에스에이
Publication of KR20190138650A publication Critical patent/KR20190138650A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020197031685A 2017-04-21 2018-04-20 반흔성 안구 염증성 장애의 치료를 위한 코버신 Ceased KR20190138650A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1706398.3 2017-04-21
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
GBGB1706398.3A GB201706398D0 (en) 2017-04-21 2017-04-21 Method of treatment
PCT/EP2018/060239 WO2018193120A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of cicatrising eye inflammatory disorders

Publications (1)

Publication Number Publication Date
KR20190138650A true KR20190138650A (ko) 2019-12-13

Family

ID=62028030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031685A Ceased KR20190138650A (ko) 2017-04-21 2018-04-20 반흔성 안구 염증성 장애의 치료를 위한 코버신

Country Status (8)

Country Link
US (1) US20210113658A1 (enExample)
EP (1) EP3612206A1 (enExample)
JP (2) JP7153669B2 (enExample)
KR (1) KR20190138650A (enExample)
CN (1) CN110831617A (enExample)
AU (1) AU2018253960A1 (enExample)
CA (1) CA3060331A1 (enExample)
WO (1) WO2018193120A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
WO2023224046A1 (ja) 2022-05-18 2023-11-23 旭化成株式会社 樹脂組成物の製造方法
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
WO2008113834A2 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US9290736B2 (en) * 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
CA2840270C (en) * 2011-06-22 2023-09-26 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US20170014487A1 (en) * 2014-03-04 2017-01-19 The Trustees Of Columbia University In The City Of New York Method for treating ocular inflammation
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
SMT202100688T1 (it) * 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment

Also Published As

Publication number Publication date
WO2018193120A1 (en) 2018-10-25
JP2020517643A (ja) 2020-06-18
EP3612206A1 (en) 2020-02-26
US20210113658A1 (en) 2021-04-22
CA3060331A1 (en) 2018-10-25
AU2018253960A1 (en) 2019-10-31
JP2022188170A (ja) 2022-12-20
CN110831617A (zh) 2020-02-21
JP7153669B2 (ja) 2022-10-14

Similar Documents

Publication Publication Date Title
JP7153669B2 (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
KR102656199B1 (ko) 자가면역 수포 질환의 치료를 위한 코버신
RU2689607C2 (ru) миРНК И ИХ ПРИМЕНЕНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА ORAI1
JP2018526412A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
Swamynathan et al. Corneal expression of SLURP-1 by age, sex, genetic strain, and ocular surface health
JP2012516694A (ja) 補体阻害物質としての改変ｏｍｃｉ
JP2022542889A (ja) ドライアイ疾患のためのｔｓｇ６ポリペプチドフラグメント
CN114072206B (zh) 治疗方法
DE60115475T2 (de) VARIANTEN DES DERMATOPHAGOIDES-ALLERGENS DER p 2
US20050090466A1 (en) Inhibitors of PACE4 for the treatment of arthritis
JP2001172190A (ja) 乳酸蓄積抑制剤
DK2061501T3 (en) METHOD OF TREATING RESPIRATORY DISORDERS

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210419

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230516

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230516

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I